Lorlatinib + Ramucirumab for Lung Cancer
Trial Summary
What is the purpose of this trial?
This study will test the safety of the combination of ramucirumab and lorlatinib. The researchers will test one or two different doses of lorlatinib in combination with ramucirumab to find the drug combination dose that causes few or mild side effects in participants. Once the researchers find this dose, they can test it in future participants to see if it is effective in treating their metastatic ALK-rearranged NSCLC. The researchers are also looking to see whether there are specific genes or DNA sequences associated with a response to treatment with lorlatinib and ramucirumab.
Will I have to stop taking my current medications?
The trial does not specify if you must stop all current medications, but you cannot take certain medications like antiplatelet agents or strong CYP3A inducers or inhibitors within 7 days of enrollment. If you're on full-dose anticoagulation, you must be on a stable dose for at least 14 days before joining the trial.
What data supports the effectiveness of the drug combination Lorlatinib and Ramucirumab for lung cancer?
Research shows that Ramucirumab, when combined with other drugs, has shown some effectiveness in treating advanced non-small-cell lung cancer (NSCLC), improving survival in certain cases. Additionally, combining Ramucirumab with other targeted therapies has been used to overcome resistance in lung cancer treatments.12345
Is the combination of Lorlatinib and Ramucirumab safe for humans?
Ramucirumab, used in combination with other drugs for lung cancer, is generally tolerable but can cause serious side effects like low white blood cell counts, fever, high blood pressure, and bleeding. It's important for these side effects to be monitored and managed by healthcare professionals.13567
How is the drug combination of Lorlatinib and Ramucirumab unique for lung cancer treatment?
The combination of Lorlatinib and Ramucirumab for lung cancer is unique because it pairs Lorlatinib, a targeted therapy for specific genetic mutations in lung cancer, with Ramucirumab, an anti-angiogenic drug that blocks blood vessel growth in tumors. This combination aims to target cancer cells directly while also cutting off their blood supply, potentially offering a novel approach compared to standard treatments.13567
Eligibility Criteria
This trial is for adults over 18 with ALK-rearranged non-small cell lung cancer that's metastatic or recurrent. They must have specific gene fusions, measurable lesions not previously treated with radiation, and good organ function. Prior chemotherapy is okay if recovered from side effects (except mild neuropathy or hair loss). Participants need stable anticoagulation if applicable and can't be pregnant or breastfeeding. Those in cohort 2 must have tried a second-generation ALK inhibitor.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Phase 1 Treatment
Participants receive lorlatinib 100 mg orally daily and ramucirumab 10 mg/kg intravenous infusion once every three weeks to assess safety and dose limiting toxicities
Phase 2 Treatment
Participants receive the maximum tolerated dose determined in Phase 1 to assess effectiveness in treating metastatic ALK-rearranged NSCLC
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Lorlatinib (ALK Inhibitor)
- Ramucirumab (Monoclonal Antibody)
Lorlatinib is already approved in United States, European Union, Japan, Canada for the following indications:
- Metastatic non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) rearrangement
- Advanced non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) rearrangement
- Unresectable, advanced/recurrent non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) rearrangement
- Metastatic non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) rearrangement